Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Contieri

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
European Urology|April 22, 2026
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008Niyati Lobo, Roberto Contieri, Laura Mertens, et al.
Cancer Treatment and Research Communications|April 10, 2021
Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysisFausto Petrelli, Patrizia Giannatempo, Carmen Maccagnano, et al.
European Urology|July 2, 2026
Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose WiselyRoberto Contieri, Antoine G van der Heijden, Laura S Mertens
Current Opinion in Urology|April 5, 2026
Impact of a multidisciplinary approach on outcomes in urothelial carcinomaAnne Neuenschwander, Alessandro Uleri, Elisabeth Grobet-Jeandin, et al.
Minerva Urology and Nephrology|December 18, 2025
HUGO™ RAS for radical nephroureterectomy: a new platform facing an old challengeAndrea Mari, Simone Albisinni, Roberto Contieri, et al.
Minerva Urology and Nephrology|October 23, 2025
Comment on "Parenchymal volume and functional recovery after clamped partial nephrectomy: potential discrepancies"Achille Aveta, Roberto Contieri, Francesco Passaro, et al.
Minerva Urology and Nephrology|June 23, 2026
The old standard still holds up: reading CREST, POTOMAC, and ALBAN in BCG-naive high-risk non-muscle-invasive bladder cancerAndrea Mari, Luca Lambertini, Simone Albisinni, et al.
Research and Reports in Urology|February 4, 2021
Delayed Diagnosis of a Testicular Mass During COVID-19 Pandemic in Lombardy: A Case ReportMiriam Cieri, Roberto Contieri, Camilla De Carlo, et al.
Minerva Urology and Nephrology|October 23, 2025
From vintage to vanguard: has chemoablation's prime time finally arrived in bladder cancer treatment?Savio D Pandolfo, Maria Carmen Mir, Clara Cerrato, et al.
European Urology|May 15, 2025
Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical CystectomyJosé Daniel Subiela, Pietro Scilipoti, Roberto Contieri, et al.
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
European Urology|April 22, 2026
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active surveillance versus intravesical bacillus Calmette-Guérin for high-grade T1 bladder cancer with negative second transurethral resection: the randomized noninferiority phase 3 JCOG1019 trial. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.01.008Niyati Lobo, Roberto Contieri, Laura Mertens, et al.
Cancer Treatment and Research Communications|April 10, 2021
Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysisFausto Petrelli, Patrizia Giannatempo, Carmen Maccagnano, et al.
European Urology|July 2, 2026
Re: Twelve-month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-sparing Therapy for Recurrent High-grade Non-muscle-invasive Bladder Cancer: Recurrent High-risk NMIBC: One Bladder, Choose WiselyRoberto Contieri, Antoine G van der Heijden, Laura S Mertens
Current Opinion in Urology|April 5, 2026
Impact of a multidisciplinary approach on outcomes in urothelial carcinomaAnne Neuenschwander, Alessandro Uleri, Elisabeth Grobet-Jeandin, et al.
Minerva Urology and Nephrology|December 18, 2025
HUGO™ RAS for radical nephroureterectomy: a new platform facing an old challengeAndrea Mari, Simone Albisinni, Roberto Contieri, et al.
Minerva Urology and Nephrology|October 23, 2025
Comment on "Parenchymal volume and functional recovery after clamped partial nephrectomy: potential discrepancies"Achille Aveta, Roberto Contieri, Francesco Passaro, et al.
Minerva Urology and Nephrology|June 23, 2026
The old standard still holds up: reading CREST, POTOMAC, and ALBAN in BCG-naive high-risk non-muscle-invasive bladder cancerAndrea Mari, Luca Lambertini, Simone Albisinni, et al.
Research and Reports in Urology|February 4, 2021
Delayed Diagnosis of a Testicular Mass During COVID-19 Pandemic in Lombardy: A Case ReportMiriam Cieri, Roberto Contieri, Camilla De Carlo, et al.
Minerva Urology and Nephrology|October 23, 2025
From vintage to vanguard: has chemoablation's prime time finally arrived in bladder cancer treatment?Savio D Pandolfo, Maria Carmen Mir, Clara Cerrato, et al.
European Urology|May 15, 2025
Management Dilemma for Very High-risk Non-muscle-invasive Bladder Cancer: Real-World Data Challenge the Guideline Recommendation for Upfront Radical CystectomyJosé Daniel Subiela, Pietro Scilipoti, Roberto Contieri, et al.
Pageof 14